Matches in SemOpenAlex for { <https://semopenalex.org/work/W2249660691> ?p ?o ?g. }
Showing items 1 to 87 of
87
with 100 items per page.
- W2249660691 abstract "17073 Background: Gefitinib and erlotinib, small molecule inhibitors of the EGFR-tyrosine kinase (EGFR-TKI), can have antitumor activity in patients with advanced NSCLC. However, analysis of clinical samples and in vitro characterization of NSCLC cell lines has revealed EGFR mutations that correlate with the clinical responses. While EGFR-mutant cell lines are hypersensitive to EGFR-TKI-mediated growth inhibition and have a greater tendency to undergo apoptosis in response to EGFR inhibition, wild-type EGFR cell lines undergo growth inhibition only at high concentrations, and are resistant to apoptosis induction. Bexarotene (Targretin) is a RXR modulator with clinical activity enhancing survival in a subset of NSCLC patients. We have shown that bexarotene can suppress the growth of epithelial tumors by modulating the expression and function of the EGFR pathway. This study examined the effect of bexarotene/EGFR-TKI combinations in preclinical models of NSCLC, and evaluated the possible molecular mechanisms for cooperative antitumor activity between these agents. Results: Bexarotene enhanced the activity of gefitinib in most of the cell lines tested, and did so regardless of their EGFR mutation status or intrinsic sensitivity to gefitinib alone. Resistant lines were sensitized by the combination, which decreased gefitinib IC50s to clinically achievable concentrations. Bexarotene increased the pro-apoptotic activity of both gefitinib and erlotinib, an effect which was paralleled by enhanced repression of p-Akt and p-Her2 levels by the combinations. In ex vivo cultures of human NSCLC explant tissue, the addition of bexarotene enhanced the growth inhibitory activity of both gefitinib and erlotinib. Finally, combinations of bexarotene and EGFR-TKI produced growth inhibition of TKI-resistant A427 NSCLC xenograft tumors that was superior to either agent alone. Conclusions: These results indicate that bexarotene can sensitize NSCLC cells which are unresponsive to the effects of EGFR-TKIs, resulting in cooperative growth inhibition and apoptosis induction. Combination therapy using bexarotene in conjunction with EGFR-TKIs may provide a powerful new therapeutic strategy. [Table: see text]" @default.
- W2249660691 created "2016-06-24" @default.
- W2249660691 creator A5006279759 @default.
- W2249660691 creator A5007269830 @default.
- W2249660691 creator A5010623992 @default.
- W2249660691 creator A5028018892 @default.
- W2249660691 creator A5058945914 @default.
- W2249660691 creator A5063621147 @default.
- W2249660691 creator A5064622016 @default.
- W2249660691 creator A5080619491 @default.
- W2249660691 date "2006-06-20" @default.
- W2249660691 modified "2023-09-27" @default.
- W2249660691 title "Cooperative antitumor activity between the retinoid X receptor (RXR)-selective agonist bexarotene and EGFR-tyrosine kinase inhibitors in preclinical models of NSCLC" @default.
- W2249660691 doi "https://doi.org/10.1200/jco.2006.24.18_suppl.17073" @default.
- W2249660691 hasPublicationYear "2006" @default.
- W2249660691 type Work @default.
- W2249660691 sameAs 2249660691 @default.
- W2249660691 citedByCount "1" @default.
- W2249660691 countsByYear W22496606912019 @default.
- W2249660691 crossrefType "journal-article" @default.
- W2249660691 hasAuthorship W2249660691A5006279759 @default.
- W2249660691 hasAuthorship W2249660691A5007269830 @default.
- W2249660691 hasAuthorship W2249660691A5010623992 @default.
- W2249660691 hasAuthorship W2249660691A5028018892 @default.
- W2249660691 hasAuthorship W2249660691A5058945914 @default.
- W2249660691 hasAuthorship W2249660691A5063621147 @default.
- W2249660691 hasAuthorship W2249660691A5064622016 @default.
- W2249660691 hasAuthorship W2249660691A5080619491 @default.
- W2249660691 hasConcept C101544691 @default.
- W2249660691 hasConcept C104317684 @default.
- W2249660691 hasConcept C126322002 @default.
- W2249660691 hasConcept C128821507 @default.
- W2249660691 hasConcept C170493617 @default.
- W2249660691 hasConcept C2775954498 @default.
- W2249660691 hasConcept C2778820923 @default.
- W2249660691 hasConcept C2778938600 @default.
- W2249660691 hasConcept C2779438470 @default.
- W2249660691 hasConcept C2780580887 @default.
- W2249660691 hasConcept C2781121885 @default.
- W2249660691 hasConcept C42362537 @default.
- W2249660691 hasConcept C502942594 @default.
- W2249660691 hasConcept C55493867 @default.
- W2249660691 hasConcept C63932345 @default.
- W2249660691 hasConcept C68484354 @default.
- W2249660691 hasConcept C71924100 @default.
- W2249660691 hasConcept C758759 @default.
- W2249660691 hasConcept C86339819 @default.
- W2249660691 hasConcept C86803240 @default.
- W2249660691 hasConcept C98274493 @default.
- W2249660691 hasConceptScore W2249660691C101544691 @default.
- W2249660691 hasConceptScore W2249660691C104317684 @default.
- W2249660691 hasConceptScore W2249660691C126322002 @default.
- W2249660691 hasConceptScore W2249660691C128821507 @default.
- W2249660691 hasConceptScore W2249660691C170493617 @default.
- W2249660691 hasConceptScore W2249660691C2775954498 @default.
- W2249660691 hasConceptScore W2249660691C2778820923 @default.
- W2249660691 hasConceptScore W2249660691C2778938600 @default.
- W2249660691 hasConceptScore W2249660691C2779438470 @default.
- W2249660691 hasConceptScore W2249660691C2780580887 @default.
- W2249660691 hasConceptScore W2249660691C2781121885 @default.
- W2249660691 hasConceptScore W2249660691C42362537 @default.
- W2249660691 hasConceptScore W2249660691C502942594 @default.
- W2249660691 hasConceptScore W2249660691C55493867 @default.
- W2249660691 hasConceptScore W2249660691C63932345 @default.
- W2249660691 hasConceptScore W2249660691C68484354 @default.
- W2249660691 hasConceptScore W2249660691C71924100 @default.
- W2249660691 hasConceptScore W2249660691C758759 @default.
- W2249660691 hasConceptScore W2249660691C86339819 @default.
- W2249660691 hasConceptScore W2249660691C86803240 @default.
- W2249660691 hasConceptScore W2249660691C98274493 @default.
- W2249660691 hasLocation W22496606911 @default.
- W2249660691 hasOpenAccess W2249660691 @default.
- W2249660691 hasPrimaryLocation W22496606911 @default.
- W2249660691 hasRelatedWork W2059255606 @default.
- W2249660691 hasRelatedWork W2069271031 @default.
- W2249660691 hasRelatedWork W2120208580 @default.
- W2249660691 hasRelatedWork W2131351052 @default.
- W2249660691 hasRelatedWork W2135117965 @default.
- W2249660691 hasRelatedWork W2142436130 @default.
- W2249660691 hasRelatedWork W2278537396 @default.
- W2249660691 hasRelatedWork W2411595378 @default.
- W2249660691 hasRelatedWork W2424009759 @default.
- W2249660691 hasRelatedWork W3029235022 @default.
- W2249660691 isParatext "false" @default.
- W2249660691 isRetracted "false" @default.
- W2249660691 magId "2249660691" @default.
- W2249660691 workType "article" @default.